Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 26, 2015British Journal of Clinical PharmacologyOpen Access

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

View Full Paper
Ask AI
Bookmark
Share

Key result

Exenatide raises systolic blood pressure by ~10 mmHg and heart rate alongside augmented sympathetic activity.

Why the study?

Does acute intravenous exenatide increase heart rate and sympathetic nervous system activity in healthy overweight males?

Population

10 healthy, overweight (BMI 26-31 kg/m2) Caucasian males, aged 20-27 years (mean age 22.7).

Comparison

Intravenous exenatide alone and in combination… vs Intravenous placebo (saline 0.9%).

Design

Other, open label

Follow-up

90 minutes

Authors

MSMark M. SmitsUniversity of CopenhagenMMMarcel H.A. MuskietLeiden UniversityLTLennart TonneijckAmsterdam University Medical Centers

Discussion

Loading...

Member takes

Overview

Acute exenatide may raise heart rate and blood pressure via sympathetic activation; leaves open chronic effects in type 2 diabetes.

Structured PICO

Does acute intravenous exenatide increase heart rate and sympathetic nervous system activity in healthy overweight males?

P
Population
10 healthy, overweight (BMI 26-31 kg/m2) Caucasian males, aged 20-27 years (mean age 22.7).
I
Intervention
Intravenous exenatide (loading dose of 50 ng/min for 30 min, followed by a continuous infusion of 25 ng/min) alone and in combination with the nitric oxide synthase inhibitor L-NMMA.
C
Comparator
Intravenous placebo (saline 0.9%).
O
Outcome
Changes in heart rate, blood pressure, and sympathetic nervous system activity (heart rate variability and rate-pressure product) during acute infusion.surrogate

Acute administration of exenatide increases heart rate and blood pressure through sympathetic nervous system activation rather than reflex tachycardia in healthy overweight males.

Limitations

  • Open label design
  • Inability to assess heart rate variability during the placebo phase
  • Systemic hemodynamic measurements modeled from pulse pressure waveforms
  • Healthy overweight males cannot be directly extrapolated to patients with type 2 diabetes
  • Intravenous administration instead of the clinically used subcutaneous route

Cite This Study

Smits et al. (2015) studied this question. Exenatide increased heart rate by a mean maximum of 6.8 beats/min and systolic blood pressure by 9.8 mmHg, alongside augmented sympathetic nervous system activity.

synapsesocial.com/papers/697cda2ac8731042648bd922https://doi.org/10.1111/bcp.12843
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects2014 · 37 citations
  2. 2Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans2008 · 100 citations
  3. 3Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study2011 · 133 citations
  4. 4Prognostic value of home heart rate for cardiovascular mortality in the general populationThe Ohasama study2004 · 92 citations
  5. 5Pulse contour cardiac output derived from non‐invasive arterial pressure in cardiovascular disease2010 · 200 citations